Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2018
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumabKoichi Sato, Hiroaki Akamatsu, Eriko Murakami, et al.Cancer Immunology, Immunotherapy : CII|January 17, 2022
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitorsYuhei Harutani, Yuichi Ozawa, Eriko Murakami, et al.Cancer Medicine|March 8, 2024
Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: A randomized phase II trialEriko Murakami, Hiroaki Akamatsu, Shunsuke Teraoka, et al.The Oncologist|April 17, 2020
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung CancerHiroaki Akamatsu, Eriko Murakami, Jun Oyanagi, et al.Journal of Pain and Symptom Management|November 22, 2023
A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer PatientsEri Takase, Hiroaki Akamatsu, Shunsuke Teraoka, et al.Cancer Science|October 21, 2020
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50Yuichi Ozawa, Yuhei Harutani, Jun Oyanagi, et al.Pageof 2